SLC5A2 and type 2 diabetes mellitus: Results from randomized placebo-controlled trials have demonstrated that in subjects with T2DM and atherosclerotic cardiovascular disease, both SGLT2 inhibitors and GLP1-RAs showed proven cardiovascular benefits, including reduced hospitalization and mortality risk.